The FDA released a post-workshop strategy document covering Biosimilar User Fee Act (BsUFA) III priorities, including future needs for interchangeable biosimilar development. The agency outlined commitments tied to a scientific workshop on interchangeable products and a subsequent draft strategy to be issued for public comment after the workshop. The document synthesizes feedback from a Sept. 19, 2025 workshop and details how FDA plans to shape its scientific and regulatory priorities as the market for biosimilars expands. For manufacturers, the guidance pipeline impacts development planning, data packages, and interchangeability studies required for broader substitution pathways. Overall, the strategy work aims to reduce regulatory uncertainty around interchangeability—an area that can determine uptake speed once biosimilars reach market.